(CRL) Charles River Laboratories - Ratings and Ratios

Charles River Laboratories International, Inc. (NYSE:CRL) is a global leader in non-clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. Headquartered in Wilmington, Massachusetts, the company operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment specializes in providing high-quality research models, including genetically engineered rodents, along with associated services such as insourcing solutions and diagnostic testing. The DSA segment focuses on early drug discovery and safety assessment, offering services like toxicology, pathology, and pharmacokinetics. The Manufacturing Solutions segment provides specialized testing for biologics and pharmaceuticals, leveraging platforms like Logica from Valo Health to accelerate drug development. Founded in 1947, Charles River Laboratories has established itself as a critical partner in advancing drug discovery and development processes.

Based on the provided data, here is a 3-month forecast: - Technical Outlook: - The stock is currently trading below its SMA 20, 50, and 200, indicating bearish momentum. - ATR of 8.34 suggests moderate volatility, with potential price swings of ±8-10% over the next 3 months. - If the stock breaks below $114.66, it may test support near $110, with resistance at $122.37 (SMA 20). - Fundamental Analysis: - The company’s P/S ratio of 1.29 and P/B ratio of 1.50 indicate reasonable valuation relative to its peers. - A forward P/E of 11.22 suggests investor expectations of improved earnings. - With a market cap of $5.2B and an RoE of 0.35, the company is positioned for stable growth in the life sciences sector.